Corpus Intelligence IC Memo — STONECREST 2026-04-26 15:56 UTC
IC Memo — STONECREST
Investment Committee Memorandum | MI | 182 beds | Grade C | EBITDA uplift $4.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

STONECREST

CCN 234038 | WAYNE, MI | 182 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

STONECREST is a 182-bed safety-net/medicaid heavy in WAYNE, MI with $60.0M in net patient revenue and a 22.9% operating margin. The hospital serves a payer mix of 10.3% Medicare, 65.9% Medicaid, and 23.8% commercial.

Thesis: Turnaround. Our ML models identify $4.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 22.9% to 30.3% (+736bps).

Net Revenue HCRIS$60.0M
Current EBITDA COMPUTED$13.8M
Operating Margin COMPUTED22.9%
Occupancy HCRIS90.8%
Revenue / Bed COMPUTED$330K
Net-to-Gross HCRIS39.8%
Distress Probability ML56.0%

2. Market Context & Competitive Position

163
MI Hospitals
-5.2%
State Median Margin
55
Comparable Hospitals

MI has 163 Medicare-certified hospitals with a median operating margin of -5.2%. The target's margin of 22.9% places it above the state median. Among 55 size-comparable peers (91-364 beds), the median margin is -7.1%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (91-364), prioritizing same-state peers. 55 hospitals in the comp set.

HospitalStateBedsRevenueMargin
STONECREST (Target)MI182$60.0M22.9%
W.A. FOOTE MEMORIAL HOSPITALMI331$681.8M-9.0%
TRINITY HEALTH MUSKEGONMI262$621.2M-15.5%
TRINITY HEALTH GRAND RAPIDSMI271$601.8M-27.3%
HENRY FORD HEALTH MACOMB HOSPIMI303$584.5M-6.9%
MYMICHIGAN MEDICAL CENTER MIDLMI195$537.8M-9.6%
METROPOLITAN HOSPITALMI201$512.0M-11.3%
LAKELAND MEDICAL CENTER ST. JMI235$488.2M-3.6%
TRINITY HEALTH OAKLANDMI333$480.5M-7.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $4.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.3M+210bp18mo
Cost to Collect4.5%2.5%$1.2M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.2M+198bp12mo
A/R Days Reduction5200.0%3800.0%$730K+122bp9mo
Clean Claim Rate88.0%96.0%$38K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.3M
Cost to Collect
$1.2M
Denial Rate Reduction
$1.2M
A/R Days Reduction
$730K
Clean Claim Rate
$38K
Total EBITDA Uplift$4.4M
Current EBITDA$13.8M
+ RCM Uplift+$4.4M
Pro Forma EBITDA$18.2M
Current Margin22.9%
Pro Forma Margin30.3%
WC Released (1x)$2.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$21.2M$134.9M6.37x44.8%
Base (11x exit)10.0x11.0x$21.2M$155.3M7.34x49.0%
Bull Case9.0x11.0x$19.0M$176.7M9.28x56.1%
Bull (12x exit)9.0x12.0x$19.0M$198.4M10.42x59.8%
Bear Case11.0x10.0x$23.3M$105.9M4.55x35.4%
Bear (11x exit)11.0x11.0x$23.3M$124.1M5.33x39.8%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (65.9%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 56.0% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 55 hospitals with 91-364 beds
  • Same-state prioritization (n=56)
  • Comp margins: P25=-13.4% / P50=-7.1% / P75=-0.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.